Clinical systems · Portable AI brain MRI
Hyperfine
Hyperfine is a publicly traded medical technology company in Guilford, Connecticut, whose Swoop system is an FDA-cleared, AI-powered portable MRI for the brain that plugs into a standard outlet and can be used at the bedside without a shielded MRI suite.
Strong fit
- ICUs and emergency departments that need brain imaging without transporting unstable patients
- Neurology clinics that want in-office brain MRI without building a conventional suite
- Hospitals expanding stroke and neurocritical programs where CT is not enough and a full MRI is hard to get
Weak fit
- Teams that need whole-body MRI or high-field detail for subtle lesions
- Hospitals that already have fast 24-hour access to conventional MRI for every neuro case
- Buyers who need a published list price before talking to sales
Bottom line
Hyperfine puts an AI-powered brain MRI on wheels so ICU and clinic teams can scan patients who cannot easily reach a conventional scanner. It is worth a close look for hospitals and neurology practices that lose time moving patients for MRI, or that lack a nearby magnet. It is not a replacement for high-field MRI when a radiologist needs the finest anatomic detail.
Score breakdown
Weights: Outcomes 35% · Product 30% · Implementation 20% · Pricing clarity 15%.
Hyperfine builds the Swoop system, a portable MRI for the brain that uses a 0.064-tesla magnet, far weaker than a conventional hospital MRI. Because the field is so low, the scanner can be rolled to a patient in an ICU, emergency department, or clinic exam room and plugged into a standard outlet, without a Faraday cage or specialized MRI staff for every scan. The company's homepage describes sequences that include T1, T2, FLAIR, and diffusion-weighted imaging, with Optive AI software that reconstructs clearer images from the ultra-low-field signal.
The product is used when a doctor needs brain imaging and moving the patient to a conventional MRI is hard or slow. Typical settings are neurocritical care, stroke programs, and outpatient neurology offices. Its closest alternatives are a conventional MRI suite, a CT scanner for urgent cases, and other point-of-care brain tools such as Ceribell for seizure detection or Eko Health for cardiac screening at the bedside. On price, Hyperfine sells capital systems through a sales process and does not publish a list price. It is in the premium portable imaging tier, well below the cost of building a new high-field suite but above most handheld diagnostic devices.
The main limit is image detail. Ultra-low-field MRI cannot match a 1.5- or 3-tesla magnet for every subtle finding, so radiologists still send many patients to conventional MRI when fine anatomy matters. Hyperfine is also still growing from a small revenue base and remains unprofitable.
In a preliminary third-quarter 2026 update, Hyperfine said revenue was about $6.0 million, up 53% from the prior quarter, nine-month revenue was about $13.8 million, and it reaffirmed full-year 2026 guidance of about $20 million to $22 million. Quarter-end cash was expected at about $37.9 million. CEO Maria Sainz pointed to growth across hospitals, office-based and wellness settings, and international Model 2 Swoop rollouts.
What clinicians and buyers say
What people like
"We can bring brain MRI to the ICU instead of rolling an unstable patient down to the magnet, which changes how fast we get an answer."
"For a neurology clinic without its own MRI, an in-office portable scanner is the difference between referring out and scanning the same day."
What people don't like
"It will not replace our 3T for every subtle lesion, and we still send those patients downstairs."
"Capital pricing is opaque until you talk to sales, which slows budget conversations."
Where customer reviews couldn't be found, our analysts attempted to give a voice to buyer sentiment, drawing on real information from review sites, forums and product documentation.
Based on: Hyperfine homepage, Hyperfine Q3 2026 preliminary results, and Hyperfine management team.
Competitor landscape
| Vendor | Overall | Ease of implementation |
|---|---|---|
| Hyperfine | 7.2 | 7.0 |
| Eko Health | 7.9 | 8.6 |
| Ceribell | 7.8 | 8.3 |
| Zeto | 7.0 | 7.4 |
| AISAP | 7.0 | 6.6 |
Pricing
| Item | Detail |
|---|---|
| Model | Capital sale of the Swoop portable MRI system, with AI software and service. List prices are not published. |
| Guidance | Full-year 2026 revenue outlook of about $20 million to $22 million, per the October 2026 preliminary update. |
| What drives cost | Number of systems, site of care, service contracts, and any AI software options. |
Leadership
Maria SainzPresident and CEO- Tom Teisseyre, PhDChief Operating Officer
- Edmond Knopp, MDChief Medical Officer
Recent news
- October 2026: Hyperfine reported preliminary third-quarter revenue of about $6.0 million, up 53% sequentially, nine-month revenue of about $13.8 million, and reaffirmed 2026 guidance of about $20 million to $22 million, with expected cash of about $37.9 million.
- October 2026: CEO Maria Sainz said momentum spanned hospital sites, office-based and wellness settings, and international rollout of the Model 2 Swoop system, in the same update.
Methodology
| Weight | Factor | What it measures |
|---|---|---|
| 35% | Customer outcomes | Whether buyers get measurable operational or clinical-workflow results after go-live |
| 30% | Product | Capability depth, reliability, and fit for the job the category buys |
| 20% | Implementation | How hard it is to stand up, integrate, train, and stabilize |
| 15% | Pricing clarity | Whether a buyer can model total cost without a mystery quote |
| Label | Meaning |
|---|---|
| Highly recommend | Strong outcomes and product with manageable caveats |
| Recommend | Solid fit for the right buyer; know the tradeoffs |
| Conditional | Only with a specific use case or heavy caveats |
| Not recommended | Avoid for most buyers in this category |
Read our full methodology for how we weight scores and assign recommend labels.